WO2008120004A1 - Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer - Google Patents
Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer Download PDFInfo
- Publication number
- WO2008120004A1 WO2008120004A1 PCT/GB2008/001184 GB2008001184W WO2008120004A1 WO 2008120004 A1 WO2008120004 A1 WO 2008120004A1 GB 2008001184 W GB2008001184 W GB 2008001184W WO 2008120004 A1 WO2008120004 A1 WO 2008120004A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- amino
- oxo
- phenyl
- benzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention porte sur un produit de combinaison comprenant un inhibiteur de MEK et un inhibiteur de B-raf, et sur des procédés pour la production d'un effet anticancer dans un patient, qui est en conséquence utile dans le traitement du cancer chez un patient. Plus spécifiquement, la présente invention porte sur : un produit de combinaison comprenant un inhibiteur de MEK et un inhibiteur de B-raf; un produit de combinaison comprenant un coffret de partie comprenant un inhibiteur de MEK et un inhibiteur de B-raf; l'utilisation du produit de combinaison dans le traitement du cancer; un procédé de traitement du cancer comprenant l'administration du produit de combinaison à un patient. Le produit de combinaison et les procédés de l'invention sont également utiles dans le traitement d'autres maladies associées à l'activité de MEK et/ou de B-raf.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90956607P | 2007-04-02 | 2007-04-02 | |
US60/909,566 | 2007-04-02 | ||
US95408907P | 2007-08-06 | 2007-08-06 | |
US60/954,089 | 2007-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008120004A1 true WO2008120004A1 (fr) | 2008-10-09 |
Family
ID=39591556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/001184 WO2008120004A1 (fr) | 2007-04-02 | 2008-04-02 | Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008120004A1 (fr) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2175885A1 (fr) * | 2007-07-30 | 2010-04-21 | Ardea Biosciences, Inc. | Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations |
WO2010068738A1 (fr) * | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mutations de mek conférant une résistance aux inhibiteurs de mek |
WO2011047238A1 (fr) * | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Combinaison |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
WO2012041987A1 (fr) * | 2010-10-01 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
WO2012059041A1 (fr) | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Nouveaux 6-arylaminopyridonecarboxamides comme inhibiteurs de mek |
WO2012145503A1 (fr) | 2011-04-21 | 2012-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
WO2013109142A1 (fr) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie |
WO2013107283A1 (fr) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Composés benzohétérocycliques et leur utilisation |
EP2640387A1 (fr) * | 2010-11-19 | 2013-09-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement utilisant un inhibiteur de la braf |
WO2013144923A1 (fr) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration d'un inhibiteur de raf et d'un inhibiteur de mek dans le traitement du mélanome |
WO2014071183A1 (fr) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek |
WO2015041533A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Association de rock et de la voie mapk |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
WO2015156674A2 (fr) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Méthode de traitement du cancer |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
CN108349868A (zh) * | 2015-11-18 | 2018-07-31 | Fmc有限公司 | 用于合成可用于制备1,3,4-三嗪的中间体的方法 |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US11087354B2 (en) | 2012-08-17 | 2021-08-10 | Genentech, Inc. | Combination therapies |
EP3889254A1 (fr) * | 2010-06-09 | 2021-10-06 | Dana-Farber Cancer Institute, Inc. | Mutation de mek1 conférant une résistance à des inhibiteurs de raf et de mek |
US11376239B2 (en) | 2016-06-03 | 2022-07-05 | Array Biopharma Inc | Pharmaceutical combinations |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009961A2 (fr) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques |
US20050222163A1 (en) * | 2004-03-30 | 2005-10-06 | Pfizer Inc | Combinations of signal transduction inhibitors |
US20050256123A1 (en) * | 2003-11-19 | 2005-11-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2006024834A1 (fr) * | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf |
WO2006067446A1 (fr) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux |
WO2007044084A2 (fr) * | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation |
WO2007059111A2 (fr) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Activite antiangiogenese du 2-methoxyestradiol en combinaison avec des agents anticancereux |
WO2007071963A2 (fr) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Composes chimiques |
WO2007071951A1 (fr) * | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Sel de tosylate du 6-(4-bromo-2-chlorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzimidazole-5-carboxamide, inhibiteur de mek pouvant etre employe dans le traitement du cancer |
WO2008020203A1 (fr) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Dérivés de pyridinylquinazolinamine et leur utilisation comme inhibiteurs de b-raf |
-
2008
- 2008-04-02 WO PCT/GB2008/001184 patent/WO2008120004A1/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009961A2 (fr) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques |
US20050256123A1 (en) * | 2003-11-19 | 2005-11-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
US20050222163A1 (en) * | 2004-03-30 | 2005-10-06 | Pfizer Inc | Combinations of signal transduction inhibitors |
WO2006024834A1 (fr) * | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Dérivés de quinazolinone et utilisation de ces dérivés en tant qu'inhibiteurs du b-raf |
WO2006067446A1 (fr) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux |
WO2007044084A2 (fr) * | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation |
WO2007059111A2 (fr) * | 2005-11-14 | 2007-05-24 | Entremed, Inc. | Activite antiangiogenese du 2-methoxyestradiol en combinaison avec des agents anticancereux |
WO2007071951A1 (fr) * | 2005-12-21 | 2007-06-28 | Astrazeneca Ab | Sel de tosylate du 6-(4-bromo-2-chlorophenylamino)-7-fluoro-n-(2-hydroxyethoxy)-3-methyl-3h-benzimidazole-5-carboxamide, inhibiteur de mek pouvant etre employe dans le traitement du cancer |
WO2007071963A2 (fr) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Composes chimiques |
WO2008020203A1 (fr) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Dérivés de pyridinylquinazolinamine et leur utilisation comme inhibiteurs de b-raf |
Non-Patent Citations (2)
Title |
---|
CARLOS GARCÍA-ECHEVERRÍA: "Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways Journal Purinergic Signalling", JOURNAL PURINERGIC SIGNALLING, 4 June 2008 (2008-06-04), Publisher Springer Netherlands, XP002489014 * |
SHELTON J G ET AL: "Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.", LEUKEMIA (BASINGSTOKE), vol. 17, no. 9, September 2003 (2003-09-01), pages 1765 - 1782, XP002489013, ISSN: 0887-6924 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
EP2175885A1 (fr) * | 2007-07-30 | 2010-04-21 | Ardea Biosciences, Inc. | Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations |
EP2175885A4 (fr) * | 2007-07-30 | 2010-12-01 | Ardea Biosciences Inc | Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations |
US9233956B2 (en) | 2008-05-06 | 2016-01-12 | Novartis Ag | Benzene sulfonamide thiazole and oxazole compounds |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8415345B2 (en) | 2008-05-06 | 2013-04-09 | Glaxo SmithKline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8642759B2 (en) | 2008-05-06 | 2014-02-04 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
WO2010068738A1 (fr) * | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mutations de mek conférant une résistance aux inhibiteurs de mek |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
CN102655753A (zh) * | 2009-10-16 | 2012-09-05 | 葛兰素史密丝克莱恩有限责任公司 | 组合药 |
EP2488033A1 (fr) * | 2009-10-16 | 2012-08-22 | GlaxoSmithKline LLC | Combinaison |
EP2488033B1 (fr) | 2009-10-16 | 2019-06-12 | Novartis AG | Combination comprenant un inhibiteur de MEK et un inhibiteur de B-raf |
EP3560498A1 (fr) * | 2009-10-16 | 2019-10-30 | Novartis AG | Combination comprenant un inhibiteur de mek et un inhibiteur de b-raf |
WO2011047238A1 (fr) * | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Combinaison |
US8952018B2 (en) | 2009-10-16 | 2015-02-10 | Glaxosmithkline Llc | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
EP4159217A1 (fr) * | 2009-10-16 | 2023-04-05 | Novartis AG | Combination comprenant un inhibiteur de mek et un inhibiteur de b-raf |
EP2488033A4 (fr) * | 2009-10-16 | 2014-04-30 | Glaxosmithkline Llc | Combinaison |
US8703781B2 (en) | 2009-10-16 | 2014-04-22 | Glaxosmithkline Llc | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US11789022B2 (en) | 2010-06-09 | 2023-10-17 | Dana-Farber Cancer Institute, Inc. | MEK1 mutation conferring resistance to RAF and MEK inhibitors |
EP3889254A1 (fr) * | 2010-06-09 | 2021-10-06 | Dana-Farber Cancer Institute, Inc. | Mutation de mek1 conférant une résistance à des inhibiteurs de raf et de mek |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
WO2012041987A1 (fr) * | 2010-10-01 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
CN103228274A (zh) * | 2010-10-01 | 2013-07-31 | 拜耳知识产权有限责任公司 | 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合 |
WO2012059041A1 (fr) | 2010-11-02 | 2012-05-10 | Centaurus Biopharma Co., Ltd. | Nouveaux 6-arylaminopyridonecarboxamides comme inhibiteurs de mek |
EP2640387A4 (fr) * | 2010-11-19 | 2014-08-20 | Glaxosmithkline Ip No 2 Ltd | Méthode de traitement utilisant un inhibiteur de la braf |
CN104689318A (zh) * | 2010-11-19 | 2015-06-10 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 使用braf抑制剂的治疗方法 |
EP2640387A1 (fr) * | 2010-11-19 | 2013-09-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement utilisant un inhibiteur de la braf |
JP2013543008A (ja) * | 2010-11-19 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | Braf阻害剤による治療方法 |
CN103402517A (zh) * | 2010-11-19 | 2013-11-20 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 使用braf抑制剂的治疗方法 |
WO2012145503A1 (fr) | 2011-04-21 | 2012-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
WO2013109142A1 (fr) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie |
US9937158B2 (en) | 2012-01-17 | 2018-04-10 | Shanghai Kechow Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013107283A1 (fr) | 2012-01-17 | 2013-07-25 | Tianjin Binjiang Pharma, Inc. | Composés benzohétérocycliques et leur utilisation |
US9290468B2 (en) | 2012-01-17 | 2016-03-22 | Shanghai Kechow Pharma, Inc. | Benzoheterocyclic compounds and use thereof |
WO2013144923A1 (fr) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration d'un inhibiteur de raf et d'un inhibiteur de mek dans le traitement du mélanome |
US20150126533A1 (en) * | 2012-03-30 | 2015-05-07 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
JP2015511632A (ja) * | 2012-03-30 | 2015-04-20 | 武田薬品工業株式会社 | メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与 |
US11783366B2 (en) | 2012-08-17 | 2023-10-10 | Genentech, Inc. | Combination therapies |
US11087354B2 (en) | 2012-08-17 | 2021-08-10 | Genentech, Inc. | Combination therapies |
WO2014071183A1 (fr) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
WO2015041533A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Association de rock et de la voie mapk |
WO2015156674A2 (fr) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Méthode de traitement du cancer |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
RU2728874C2 (ru) * | 2015-11-18 | 2020-07-31 | Фмк Корпорейшн | Способ синтеза полупродуктов, полезных для получения производных 1,3,4-триазина |
CN108349868A (zh) * | 2015-11-18 | 2018-07-31 | Fmc有限公司 | 用于合成可用于制备1,3,4-三嗪的中间体的方法 |
US11376239B2 (en) | 2016-06-03 | 2022-07-05 | Array Biopharma Inc | Pharmaceutical combinations |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008120004A1 (fr) | Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer | |
US20100004247A1 (en) | Combination comprising a mek inhibitor and an aurora kinase inhibitor 188 | |
JP7058345B2 (ja) | Bcl-2阻害剤及びMDM2阻害剤の組合せ製品並びに疾患の予防及び/又治療におけるその使用 | |
TW202027746A (zh) | 用於治療三陰性乳癌之組合療法 | |
CA2389333C (fr) | Polymorphe stable de chlorhydrate de n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, et methodes de production et utilisations pharmaceutiques dudit polymorphe | |
JP2021165286A (ja) | グルタミナーゼ阻害剤の結晶形態 | |
US20100063066A1 (en) | Raf inhibitor compounds and methods of use thereof | |
JP6192708B2 (ja) | C−metプロテインキナーゼ調節物質としての新規3,5−二置換−3h−イミダゾ[4,5−b]ピリジン化合物および3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物 | |
JP2013500255A (ja) | 自食作用の強力な小分子阻害剤、およびそれの使用方法 | |
JP2013500255A5 (fr) | ||
KR20100135754A (ko) | 병용 요법 238 | |
TW200803852A (en) | Inhibitors of histone deacetylase for the treatment of disease | |
CN101541758A (zh) | 抑制trpv1的吲唑衍生物及其用途 | |
JP2008514726A (ja) | ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法 | |
CN103052627A (zh) | 作为fak抑制剂的嘧啶衍生物 | |
CN104592105A (zh) | 瑞戈非尼及其制法 | |
JP2021530554A (ja) | 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤 | |
KR20180094862A (ko) | 유방암 치료제 | |
WO2013170757A1 (fr) | Composé acide 4-aminoquinazoline hydroxamique et application comme médicament anticancéreux | |
WO2011095807A1 (fr) | Combinaisons d'inhibiteurs de mek et de hh | |
JP2015522607A (ja) | プロテインキナーゼに対する阻害活性を有するイソキノリン−5−カルボキサミド誘導体 | |
CN106916112B (zh) | 嘧啶衍生物及其制备方法和在医药上的应用 | |
US20090291961A1 (en) | Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer | |
TW201602086A (zh) | 作為抗癌藥物之芳基胺取代的喹喔啉 | |
TW202135792A (zh) | 治療癌症之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08736885 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08736885 Country of ref document: EP Kind code of ref document: A1 |